What Happened When Alex Kenjeev Paid His Student Loan in Cash
How to Save Money at the Movie Theater
"Isis Pharmaceuticals (ISIS) as been a leader in genomics-based drug research since the late 1990s and has amassed an impressive intellectual property portfolio," notes biotech specialist John McCamant.
The editor of The Medical Technology Stock Letter explains, "ISIS has successfully applied their technology to take advantage of the emergence of new genetic information. More specifically, and most important for investors, has been the ability to prolifically patent their discoveries.
"Their proprietary technologies include methods of screening drug candidates, chemical modification of the drugs to improve their efficacy, safety and biostability and methods for the manufacture of DNA and RNA-based therapeutics.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
